Dehghani Mohammad Hossein, Saghafi Fatemeh, Bordbari Zeinab, Zare-Kamali Javad, Jafari-Nedooshan Jamal, Sahebnasagh Adeleh
Department of Anesthesiology and Critical Care, Shahid Rahnemoun Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Department of Clinical Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Nutr Clin Pract. 2023 Apr;38(2):402-410. doi: 10.1002/ncp.10895. Epub 2022 Jul 9.
Probiotics are beneficial live microorganisms that can modify the gut microbiota. It is assumed that they help improve enteral feeding intolerance (EFI) and nosocomial infections in critically ill patients. The present clinical trial aimed to investigate the efficacy of synbiotics in improving EFI and oropharyngeal aspiration in patients admitted to the intensive care unit (ICU).
This randomized clinical trial was conducted on 105 critically ill patients admitted to the ICU of a tertiary referral hospital affiliated with a medical university. The patients were randomly assigned to either a synbiotic or control group and underwent 7 days of investigation. The primary end point was reduced gastric residual volume, which is suggestive of an improvement in EFI. The secondary end point included requirement for prokinetics, frequency of aspiration, duration of mechanical ventilation, length of ICU stay, and level of consciousness.
The present clinical trial showed that synbiotic intervention has resulted in a significantly diminished requirement for prokinetics (P = 0.019), fewer oropharyngeal aspirations (P = 0.01), improved volume of bolus administration, and decreased gastric residual volume during the 7-day follow-up period. The patients who received synbiotic had an improved level of consciousness (P = 0.01).
This clinical trial showed that the prescription of synbiotic from the initial days of enteral feeding has resulted in a significantly diminished requirement for prokinetics, less oropharyngeal aspiration, decreased gastric residual volume, improved volume of bolus administration, and hence, better tolerance of enteral feeding.
益生菌是有益的活微生物,可改变肠道微生物群。据推测,它们有助于改善重症患者的肠内喂养不耐受(EFI)和医院感染。本临床试验旨在研究合生元对改善重症监护病房(ICU)患者的EFI和口咽误吸的疗效。
本随机临床试验对一所医科大学附属三级转诊医院ICU收治的105例重症患者进行。患者被随机分为合生元组或对照组,并接受7天的观察。主要终点是胃残余量减少,这表明EFI有所改善。次要终点包括促动力药的需求、误吸频率、机械通气时间、ICU住院时间和意识水平。
本临床试验表明,在7天的随访期内,合生元干预显著减少了促动力药的需求(P = 0.019),减少了口咽误吸(P = 0.01),改善了推注给药量,并减少了胃残余量。接受合生元治疗的患者意识水平有所改善(P = 0.01)。
本临床试验表明,从肠内喂养开始的最初几天就使用合生元可显著减少促动力药的需求,减少口咽误吸,降低胃残余量,改善推注给药量,从而提高肠内喂养的耐受性。